ICER to develop a California state unsupported price increase report funded by the California Health Care Foundation

ICER

3 March 2022 - Expanded funding supports the development of two annual “Unsupported Price Increase” reports specific to drugs identified through the California drug price transparency law.

The Institute for Clinical and Economic Review has received a new grant from the California Health Care Foundation to develop 1) two annual unsupported price increase reports specific to California, and 2) a policymaker guide outlining how to use comparative effectiveness research to ensure that patients have fair access to fairly priced drugs.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder